Cardinal Health, Inc. – Consensus Indicates Potential -1.5% Downside

DirectorsTalk Interviews

Cardinal Health, Inc. with ticker code (CAH) have now 13 analysts covering the stock. The analyst consensus points to a rating of ‘Hold’. The range between the high target price and low target price is between 80 and 56 and has a mean target at 69.54. With the stocks previous close at 70.63 this would indicate that there is a downside of -1.5%. The day 50 moving average is 62.01 while the 200 day moving average is 56.08. The market cap for the company is $19,046m. Visit the company website at: https://www.cardinalhealth.com

The potential market cap would be $18,752m based on the market concensus.

Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.

Share on:

Latest Company News

EDX Medical launches BC95 bowel cancer testing service in the UK

EDX Medical Group has announced the UK launch of its BC95 bowel cancer testing service, designed to improve early detection and assess hereditary risk.

Elemental Royalty Poised for Growth in the Mid-Tier Precious Metals Sector, Says Cantor Fitzgerald

Elemental Royalty Corp. receives Buy rating from Cantor Fitzgerald, citing strong growth outlook and robust royalty cash flows.

Cora Gold Funding Boost Fuels Sanankoro’s Push Toward Key Permit Milestone (Video)

Cora Gold CEO Bert Monro outlines how fresh funding will accelerate permitting at the Sanankoro Gold Project in Mali — and why signs from the government are giving the company new momentum heading into 2026

Tekmar Group secures second €8m offshore wind contract

Tekmar Group has been awarded a contract worth more than €8 million to supply its 10th Generation Cable Protection System for a major UK offshore wind farm.

Ilika ships first Stereax M300 prototypes

Ilika has begun shipping prototype Stereax M300 solid state batteries to customers, marking a key commercial milestone for the company.

Thor Energy updates HY-Range exploration and portfolio strategy

Thor Energy has provided an update on exploration planning at its HY-Range hydrogen and helium project in South Australia, including preparations for a major 2D seismic survey in 2026.

    Search

    Search